AGL 40.10 Decreased By ▼ -0.90 (-2.2%)
AIRLINK 127.80 Decreased By ▼ -0.34 (-0.27%)
BOP 6.60 Decreased By ▼ -0.10 (-1.49%)
CNERGY 4.60 Increased By ▲ 0.08 (1.77%)
DCL 8.58 Decreased By ▼ -0.03 (-0.35%)
DFML 41.40 Increased By ▲ 0.31 (0.75%)
DGKC 86.50 Decreased By ▼ -0.63 (-0.72%)
FCCL 32.13 Decreased By ▼ -1.26 (-3.77%)
FFBL 65.40 Decreased By ▼ -0.01 (-0.02%)
FFL 10.27 Decreased By ▼ -0.20 (-1.91%)
HUBC 110.60 Decreased By ▼ -0.03 (-0.03%)
HUMNL 14.70 Decreased By ▼ -0.60 (-3.92%)
KEL 5.15 Increased By ▲ 0.17 (3.41%)
KOSM 7.15 Decreased By ▼ -0.28 (-3.77%)
MLCF 41.69 Decreased By ▼ -1.30 (-3.02%)
NBP 60.20 Decreased By ▼ -0.22 (-0.36%)
OGDC 194.48 Decreased By ▼ -3.16 (-1.6%)
PAEL 27.95 Decreased By ▼ -1.06 (-3.65%)
PIBTL 7.98 Decreased By ▼ -0.28 (-3.39%)
PPL 150.52 Decreased By ▼ -3.64 (-2.36%)
PRL 27.08 Increased By ▲ 2.08 (8.32%)
PTC 16.08 Decreased By ▼ -0.01 (-0.06%)
SEARL 78.20 Decreased By ▼ -0.25 (-0.32%)
TELE 7.42 Increased By ▲ 0.05 (0.68%)
TOMCL 35.70 Decreased By ▼ -0.39 (-1.08%)
TPLP 7.90 Decreased By ▼ -0.17 (-2.11%)
TREET 15.87 Decreased By ▼ -0.09 (-0.56%)
TRG 52.70 Decreased By ▼ -0.66 (-1.24%)
UNITY 26.65 Decreased By ▼ -0.06 (-0.22%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 9,920 Decreased By -52.1 (-0.52%)
BR30 30,751 Decreased By -346.3 (-1.11%)
KSE100 93,225 Decreased By -423.8 (-0.45%)
KSE30 28,885 Decreased By -132.9 (-0.46%)

Searle Company Limited (Searle) has entered into a license agreement with China’s Mabwell Pharmaceuticals, under which Searle will manufacture, register, and market the Denosumab Biosimilars drugs in Pakistan.

Searle, which is principally engaged in the manufacture of pharmaceutical and other consumer products, shared the development in a notice to the Pakistan Stock Exchange (PSX) on Wednesday.

“Mabwell is pleased to partner with Searle Co Ltd to commercialize and localize Denosumab biosimilars in Pakistan,” said Dr Datao Liu, Co-founder, Chairman of the Board, and CEO of Mabwell in a statement.

Liu said Pakistan is an important country in China’s Belt and Road Initiative with a large market and ‘great demand’. “This partnership will benefit the patients in Pakistan by providing high quality affordable biological medicines,” he added.

Similar sentiments were expressed by Syed Nadeem Ahmed, Group Managing Director and CEO of Searle Company Limited.

“Partnership with Mabwell is an integral part of our strategy to develop further our biotechnology business in Pakistan,” said Nadeem Ahmed.

“The goal of this project is not only to bring Mabwell products to Pakistan, but also to establish cooperation with such an innovative company as Mabwell.

“This cooperation also represents an important milestone for Searle Co Ltd., and for our patients in Pakistan that will ensure the social benefit from an increased access to high-quality affordable medicines” he added.

Searle is one of the top pharmaceutical companies in Pakistan having eight state-of-the art manufacturing facilities and global presence in 18 countries.

Comments

Comments are closed.

Fazeel Siddiqui (Overseas Pakistani) Jul 12, 2023 06:54pm
Much need good news.
thumb_up Recommended (0)
USMAN GHANI Jul 13, 2023 03:01pm
Searle must enter in manufacturing or initially refilling . Biologicals. to start with blood derivatives and following up of Vaccines .
thumb_up Recommended (0)